Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: Recent Advances

<p>Hepatocellular carcinoma (HCC) remains the third leading cause of cancer-related mortality worldwide. There were approximately 865000 new cases and 758000 new deaths from HCC globally in 2022, with a projected 77% increase in cases by 2050. Based on landmark clinical trials, such as IMbrave150, H...

Descripción completa

Detalles Bibliográficos

Autores principales:	Wang, Boya, Dong, Liyan, Zou, Deli, Qi, Xingshun
Formato:	Capítulo de libro
Lenguaje:	inglés
Publicado:	IntechOpen 2026
Materias:	Health Sciences
Acceso en línea:	https://www.intechopen.com/chapters/1237170
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!